ReST built an agile organisation composed of management and operational talents
ReST built an agile organisation composed of management and operational talents
Gilles RUBINSTENN, PhD, MBA
CEO and CSO
After completing a PhD in medicinal chemistry and quantum physics at Ecole Normale Superieure in Paris, Gilles Rubinstenn joined L’OREAL R&D in 1998 where he learned scientific management and innovation (becoming inventor in 34 patents, including the formulation supporting the $2B Lancôme Absolue® franchise). After leading the innovation team of EUROTAB and establishing the Pierre-Gilles de Gennes Foundation, he has chaired the SATT idfinnov (now erganeo) a private tech-transfer office and seed investment agency operating over the largest biomedical cluster of the Paris area. In 2013, together with 3 partners he co-founded M2i Life Sciences, which became within 6 years a world leader for biocontrol, replacing pesticides with insects’ pheromones, and closed one of the largest 2019 French Tech Investment round. In M2i, Gilles has held various positions, first restructuring the marketing teams, them leading the Pharma business unit and finally acting as CFO supporting the successful conclusion of the M2i round B and post-closing operations. Since 2018 he has been working at building the foundation of ReST while advising the President of AFM TELETHON on Bioproduction. Gilles Rubinstenn holds an EMBA from INSEAD and teaches entrepreneurship in various business Schools.
Dr Florent Perin-Dureau, MD, MSc
Florent Perin-Dureau graduated from the Ecole Normale Superieure – Sorbonne University joined MD- MsC program in 2004. His research Thesis was on the neuropharmacology of NMDA receptors. He then became assistant professor in anesthesiology and neurointensive care at hospital Pitie-Salpetriere. He practiced as senior intensivist in Foundation Rothschild and hospital Foch. He was there specifically in charge of supporting critical care patient’s families through their trauma. Florent completed his formation with a master in strategy and management of health industries at ESSEC business school and was then appointed Director of the largest ANSM division supervising drug MA, including neurology, psychiatry, anesthesiology, pain medicine, as well as respiratory medicine, rheumatology, and internal medicine. He then returned to hospital Foch as Head of Clinical Research Department (Phase II-III trials but also Phase I, sponsored by industry and investigator-driven protocols). Since 2017, Florent has been consulting with the pharmaceutical industry, advising mainly in clinical development and market authorization process while becoming involved in the biotech start-up ecosystem. He first repositioned a spin-off of Institute Pasteur, dedicated to stem cell and regenerative medicine, then joining the management team of ReST.
Anthony Franco, JD
General Manager US
Anthony Franco is a seasoned Operations and Strategy Executive with over 20 years of experience across the Legal, Technical and Biotech industries. He holds a Bachelor’s Degree in Business Management from Southern Connecticut State University and a Juris Doctorate from Western New England School of Law. He has an established track record helping organizations define their ways of working, develop their strategy and achieve their corporate goals. Prior to joining ReST, Anthony served as the Chief Operating Officer for a Microbiome Startup where he was responsible for transforming their consumer division and establishing the pharmaceutical development program focusing on Rare Pediatric Diseases. While at Alexion for the decade prior he held numerous positions of increasing leadership in Product Development, Global Operations, Corporate Real Estate and IT, until its $39B acquisition by AstraZeneca. Early in his career, he also managed a successful legal practice focused on corporate real estate and business law. He resides in Guilford, Connecticut with his wife and two sons.
Nanobiotix US CEO
Patrick Tricoli was appointed in 2014 Chief Executive Officer of Nanobiotix Corp., the Nanobiotix US affiliate in Cambridge, MA focused on building the Nanobiotix US presence while cultivating cross-industry relationships. Additionally, and since 2020, he has been leading and implementing the partnering strategy and deal making as Global Head of Business Development at Nanobiotix. Prior to Nanobiotix, Patrick was well known for his lead roles at Sanofi in Partnering and Innovation R&D and subsequently as Head of External Innovation Europe, spanning 15 years, Europe, Asia, and the US markets. He led multiple international teams while he developed strong international business development relationships, corporate development strategies, collaborative R&D partnerships, and business opportunities. He started his career in Neuropharmacology research in both academia in Europe and in the industry at Lederle, now Pfizer in the US.
Since 2017, he has served as a New England Foreign Trade Advisor for the French government and is a board member since 2022. Patrick holds a PharmD, a Master’s degree in Pharmacology and Pharmacokinetic and an Executive MBA from ESCP Europe.
Astorg CEO & Managing Partner
Thierry co-founded Astorg in 1998 and currently leads the organisation. He is a Member of the Group Executive Committee and of the Investment Committee. Prior to this, Thierry spent 4 years with the private equity team at Suez. He began his career in 1989 at Banque Indosuez where he held several positions in London and Paris, particularly in the project finance division.
Thierry graduated from ESCP Europe.
M2i Group CEO
If we had to summarize in a few words Philippe Guerret’s atypical career path until the creation of M2i Group in 2012, we could talk about experimentation and quick responsibilities: development of PepsiCo in France, management of audiovisual rights at UGC Cinema Corp at the time of the takeover by the TV channel Canal+, IPO of Vinci and launch of airport concessions of the group, everything even before its 30th anniversary. Philippe Guerret surfed between Miami and Switzerland, exceled in the repositioning of companies in difficulty, and then specialized in duty free. With a head start, he imagined what could become his next playgroundand fell in love at first sight with the industry through the management of an industrial group producing active pharmaceutical ingredients. Finally, convinced that innovation and industry must go hand in hand, he created M2i Group with 3 partners, including Gilles Rubinstenn. The company, expert in complex molecules historically used for human health, diversified under Philippe Guerret’s leadership towards the production of innovative finished products with high added value for the biological crop treatment as an alternative to pesticides. In 10 years, after €60 millions raised, M2i hires 200 employees and has become the European leader in its sector by protecting more than 100,000 hectares worldwide. Philippe is graduated from EDHEC and is a member of the school’s ETHICS BOARD.
Aude Michaud , MSc
Aude holds a master’s degree in microbiology (2004) at the university of Dijon and joined Dow AgroSciences to experiments phytosanitary products in order to adapt their use and support farmers in their production. She learned to manage experiments prior joining the plant protection association to train winegrowers in vine diseases and orient their practices towards sustainable agriculture. In 2008, she decided to orient her career in the health field and joined many companies in medical device industry and/or pharmaceutical industry. First position was trainee at Urgo Medical where she learned the basics of clinical research prior joining the medical department of Coloplast where she consolidated knowledge and skills in clinical research and medical devices (class I and class II). From 2010 to 2012, she conducted clinical studies for Quintiles IMS dedicated to Pfizer laboratory in oncology, rheumatology, pediatrics and rare diseases. For 7 years, she held various positions in scientific & clinical affairs department of BBraun Medical in the preclinical and clinical development strategy of medical devices (class I to class III) and the implementation of clinical studies on medical devices and drugs. In 2019, Aude had the desire to discover the start-up environment and joined Quantum Surgical to lead the preclinical and clinical activities to get the CE marked of the robotized device prior joining ReST Therapeutics.
Aline Freyssin, PhD
After completing a Master degree in neurosciences at the university of Bordeaux (2014-2016), Aline Freyssin joined UCB pharma where she completed her knowledge in neurosciences and more precisely on neurovegetative diseases. She participated to the development of anti-TAU and anti-α-Synuclein antibodies and tried to developed new biomarker of Alzheimer disease. Her motivation to extend her career was stronger than her place to UCB pharma and she decided in 2017 to leave pharmaceutical industry in order to obtained a PhD. She was graduated in 2020 from a PhD in neuroscience with Alzheimer disease as a principal subject. Her desire to stay close from pharmaceutical development in neurosciences was her principal motivation to rejoined ReST therapeutics
After a preparation for the veterinary competition, the starting point of her passion for research in neurosciences, Allison Carles continued her studies with a license and a master’s degree in neuroscience at the University of Montpellier. She was deputy secretary and president of the Association of Neurosciences of the University of Montpellier (ANSUM) during these two years of master’s degree (2018-2020). While waiting to obtain a thesis funding, Allison was a study engineer at the University of Montpellier (IBMM UMR5247 & MMDN U1198) and worked for 5 months on the study of the neurotoxic effects of a single exposure of a gas in a mouse model. Her motivation and her knowledge were rewarded in 2021 by a thesis funding by ReST Therapeutics and the publication of his master’s internship results as a 2nd author at “Neuropharmacology”. Her thesis project is a comparative analysis of FENM and Memantine administration protocols on behavioral, biochemical and physiological parameters in Alzheimer’s mouse models directed by Dr T. MAURICE.
Dr. Krystal is McNeil Professor and Chair of Psychiatry at Yale and Yale-New Haven Hospital. He studies the neurobiology and treatment of psychiatric disorders. His laboratory discovered the rapid antidepressant effects of ketamine. He directs the Yale Center for Clinical Investigation, Center for the Translational Neuroscience of Alcohol, and Neuroscience Division of the National Center for PTSD. He is a member of the National Academy of Medicine; Fellow of the American Association for the Advancement of Science; co-director of the Neuroscience Forum of the National Academies of Sciences, Engineering, and Medicine; editor of Biological Psychiatry; and co-founder of Freedom Biosciences.